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Abstract
Clearance of infection with intracellular pathogens in mice involves interferon-regulated GTPases of the IRG protein family.
Experiments with mice genetically deficient in members of this family such as Irgm1(LRG-47), Irgm3(IGTP), and Irgd(IRG-47)
has revealed a critical role in microbial clearance, especially for Toxoplasma gondii. The in vivo role of another member of
this family, Irga6 (IIGP, IIGP1) has been studied in less detail. We investigated the susceptibility of two independently
generated mouse strains deficient in Irga6 to in vivo infection with T. gondii, Mycobacterium tuberculosis, Leishmania
mexicana, L. major, Listeria monocytogenes, Anaplasma phagocytophilum and Plasmodium berghei. Compared with wild-type
mice, mice deficient in Irga6 showed increased susceptibility to oral and intraperitoneal infection with T. gondii but not to
infection with the other organisms. Surprisingly, infection of Irga6-deficient mice with the related apicomplexan parasite, P.
berghei, did not result in increased replication in the liver stage and no Irga6 (or any other IRG protein) was detected at the
parasitophorous vacuole membrane in IFN-c-induced wild-type cells infected with P. berghei in vitro. Susceptibility to
infection with T. gondii was associated with increased mortality and reduced time to death, increased numbers of
inflammatory foci in the brains and elevated parasite loads in brains of infected Irga6-deficient mice. In vitro, Irga6-deficient
macrophages and fibroblasts stimulated with IFN-c were defective in controlling parasite replication. Taken together, our
results implicate Irga6 in the control of infection with T. gondii and further highlight the importance of the IRG system for
resistance to this pathogen.
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Infectionwith the obligate intracellular pathogen Toxoplasmagondii
causes disease in humans and animals [1,2]. Following oral uptake,
active invasion of host cells in the small intestine results in formation
of parasitophorous vacuoles (PV) that resist lysosome fusion and
thereby allow intracellular survival [3]. Following replication,
dissemination, and initial immune activation, the parasite forms
cysts in the central nervous system and skeletal muscle and persists
lifelong. Whereas acute infection only rarely causes symptoms in
man, severe immunosuppression (i.e., AIDS and transplantation)
may result in reactivation of latent infection presenting as
toxoplasmic encephalitis [1]. Furthermore, acute infection during
pregnancy carries a high risk of transfer to the fetus and severe
toxoplasmosis in the infant. Limitation of parasite replication and
cyst formation relies on the development of a type 1 T helper (Th1)
response involving secretion of IL-12 by dendritic cells [4] and
interferon-gamma (IFN-c) and tumor necrosis factor (TNF) by T
cells and natural killer (NK) cells [5]. Murine models have been used
extensively to study the immunopathogenesis of infection [5,6].
IFN-c has been identified asa key cytokine secreted mostly by CD4
+
T cells and NK cells [7,8]. The functions of IFN-c include activation
of macrophages and other antigen-presenting cells including
astrocytes [9–11]. Mice on the C57BL/6 background (H-2
b
haplotype) develop a fatal chronic progressive infection; pathologic
changes include parasite-associated follicular infiltrations in the
brain parenchyma and meninges similar to toxoplasmic encephalitis
in AIDS patients [12,13]. In contrast, mice on the BALB/c (H-2
d)
background and outbred strains of mice are resistant to the infection
and do not develop symptoms of encephalitis [12].
Resistance against T. gondii in mice is partly dependent upon
various members of the interferon-inducible 47 kDa GTPase
family, recently designated the immunity-related GTPase (IRG)
family [14,15]. Twenty-three IRG genes have been identified in
C57BL/6 mice [16]. Of those, the majority have been shown to be
inducible by IFN-c, including Irgm1 (formerly LRG-47), Irgm3
(formerly IGTP), Irgd (formerly IRG-47), Irgm2 (formerly GTPI),
Irga6 (formerly IIGP), and Irgb6 (formerly TGTP) [16–21].
Targeted disruption of Irgm1 [22], Irgd [22] and Irgm3 [23] has
revealed significant roles for each of these gene products in
immunity in vivo against intracellular pathogens (reviewed in [24]).
Irgm1 knockout mice were susceptible to a range of organisms
including intracellular protozoa (Leishmania major, Trypanosoma cruzi
and T. gondii) and intracellular bacteria (Listeria monocytogenes,
Salmonella typhimurium, Mycobacterium avium, M. tuberculosis and
Chlamydia trachomatis) (reviewed in [24]) though the basis for this
dramaticlossofimmune competence hasrecentlybeen re-evaluated
[25]. In contrast, mice lacking Irgd were susceptible to infection
with T. gondii but resistant to L. monocytogenes, S. typhimurium, M.
tuberculosis, and MCMV (reviewed in [24]). Irgm3 knockout mice
weresusceptibleto infectionwithT. gondii, L. major,a n dC. trachomatis
but showed resistance to T. cruzi, L. monocytogenes, S. typhimurium, M.
avium, M. tuberculosis and MCMV (reviewed in [24]) The role of
IIGP/Irga6 is lesswell documented. However, likemany otherIRG
proteins Irga6 also accumulates rapidly on the parasitophorous
vacuole membrane (PVM) surrounding intracellular parasites
[26,27]. Astrocytes isolated from the Cologne strain of Irga6-
deficient mice described here had a partial loss of IFN-c-mediated
growth restriction of T. gondii [26], but no other details of the
phenotype or of the gene disruption were given. Preliminary results
from the same knock-out strain suggested no significant loss of
in vivo resistance [14]. In the present paper we now provide full
documentation for both this and an independently derived Irga6-
deficient mouse strain from Berlin.
We show that both the Cologne and Berlin strains of Irga6-
deficient mice have increased susceptibility to oral or intraperito-
neal infection with T. gondii. Susceptibility to infection with T.
gondii is associated with increased mortality, increased numbers of
inflammatory foci in the brains and elevated parasite loads in
organs of infected mice. Irga6-deficient macrophages stimulated
with IFN-c in vitro showed a partial defect in controlling parasite
replication. Taken together, results of the present study add Irga6
to the list of IRG proteins whose loss in mice leads to increased
susceptibility to T. gondii. Indeed, the significance of T. gondii as a
major target of the IRG resistance system is emphasized by the
lack of a detectable susceptibility phenotype of the Irga6-deficient
animals for a long list of other intracellular pathogens, including
the related apicomplexan parasite, Plasmodium berghei, which is
assayed here for the first time in the context of IRG protein-
mediated resistance.
Materials and Methods
Ethics statement
All animal experiments were conducted under the regulations
governing animal experimentation in the relevant jurisdictions.
Specific license numbers and authorities are as follows:
Aebischer: LaGeSo Berlin No. G 0170.01
Bogdan: Regierungspra ¨sidium Freiburg No., 35-9185.81/
G-03/70
Howard: LANOV Nordrhein-Westfalen No. 44.07.189
Liesenfeld: LaGeSo Berlin Nos. G 0258/04, 0113/06, 0114/06,
0109/08, 0146/10
Mota: All protocols were approved by the Animal Care
Committee of the Instituto de Medicina Molecular, Lisbon,
following Institutional, National, and European Union guidelines.
Reichmann: Du ¨sseldorf No. 50.05-230-63/04
Specht: Bonn No. 50.203.2BN15,50/05
von Stebut: Landesuntersuchungsamt Rheinland-Pfalz No. 23
177/07/G08-1-010
Zerrahn: LaGeSo Berlin No. G0177-01
Gene targeting and mice
Mice were generated at the Max Planck Institute for Infection
Biology (MPIIB) in Berlin and independently with a different
strategy at the Institute for Genetics (IG), University of Cologne. At
MPIIB, the IRG locus was targeted in 129/OLA-derived E14 ES
cells by replacement of the single coding exon of Irga6 with a
neomycin resistance cassette. The deleted locus was backcrossed
onto the 129/SvJ and C57BL/6 strains and bred to homozygosity.
In Cologne, the Irga6 long coding exon was flanked by LoxP sites in
Bruce 4 (C57BL/6) ES cells, and this exon was subsequently deleted
in the germ-line by breeding mice carrying the floxed locus with
Cre-deleter strain. The deleted locus was backcrossed to C57BL/6
and bred to homozygosity. See Figure S1 and Figure S2 for further
details and verification of the two gene targeting strategies.
Mice and infection
The homozygous line derived from the Berlin strategy is
designated B-Irga6
2/2 throughout the paper, and the line derived
from the Cologne strategy K-Irga6
2/2. When the genotype is not
specified, mice from the two sources are referred to as B-strain and
K-strain All mice were kept according to national guidelines for
animal care in SPF animal facilities.
T. gondii
Cysts of the type II ME49 or DX strains of T. gondii, avirulent
in mice, were obtained from homogenized brains of mice
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J and C57BL/6 control mice and B-Irga6
2/2 mice on the same
backgrounds (laboratory of O. Liesenfeld) were infected perorally
with 10 cysts in 0.3 ml phosphate buffered saline (PBS: pH 7.4) by
gavage. K-C57BL/6 and K-Irga6
2/2 mice were infected i.p. with
bradyzoites isolated from 5 cysts (laboratory of G. Reichmann), and
also according to the Berlin protocol (laboratory of O. Liesenfeld).
M. tuberculosis
For infection with M. tuberculosis, B-strain mice (laboratory of J.
Zerrahn) were aerosol-challenged with 100–200 colony-forming
units (CFU) of M. tuberculosis H37Rv bacteria per lung using an
aerosol chamber (Glas-Col) as described recently [28]. The
inoculum was confirmed at day 1 post-infection (p.i.) by plating
the lungs of control mice. Bacterial load per organ was analyzed by
plating complete lungs and spleens of mice onto Middlebrook
7H11/ampicillin plates.
L. monocytogenes
L. monocytogenes strain EGD bacteria were freshly prepared for
infection from aliquots stored at 280uC. Aliquots were thawed
and bacterial titers were determined by plating serial dilutions on
TSB or blood agar plates. For intravenous (i.v.) infection, bacteria
were injected in a volume of 200–500 ml phosphate buffered saline
(PBS) into the lateral tail vein of B strain (laboratory of J. Zerrahn)
or K strain mice (laboratory of O. Utermo ¨hlen).
L. major and L. mexicana
B-strain mice were infected subcutaneously with 2610
6 station-
ary phase promastigotes in 20 ml of PBS into the left hind footpads
The inocula consisted of stationary phase promastigotes of L.
mexicana (MNYC/BZ/62/M379) or L. major (WHOM/IR/-/173).
Stationary phase L. major promastigotes were further enriched for
metacyclic parasites by density centrifugation as described previ-
ously [29]. Inocula were opsonized before infection with 5% C5-
deficientserumobtainedfromB10.D2/OsNjmice,byincubationat
37uC for 30 min (laboratory of T. Aebischer). Infective stage
(metacyclic) promastigotes of L. major clone VI (MHOM/IL/80/
Friedlin) were isolated from stationary culture by lack of
agglutination with peanut agglutinin (Vector Laboratories, Burlin-
game,CA).K strainmicewereinfected byinjection of 10 mlof PBS
containing 2610
5 (high dose) or 10
3 (physiologically relevant low
dose infection) non-opsonised metacyclic promastigotes into the
dorsal dermis of the left ears. Lesion volumes were measured weekly
in 3 dimensions using a caliper, and are reported (in mm
3)a s
ellipsoids [(a/2b/2c/2)4/3] [30] (laboratory of E. von Stebut).
A. phagocytophilum
A. phagocytophilum strain Webster (formerly human granulocytic
ehrlichiosis (HE) agent Webster strain) [31] was cultured in HL60
cells grown in RPMI 1640 medium supplemented with 1% fetal
calf serum in 5% CO2 and used for mouse infection experiments
as described previously [32]. Three K strain and three C57BL/6
mice per group were infected i.p. and sacrificed at days 3, 7, and
14 p.i. The bacterial load in blood, spleen, and lung was measured
by quantitative PCR as copy number of A. phagocytophilum per copy
number of mouse G6PDH [32]. The infectious dose was
determined retrospectively and consisted of 1610
5 genome
equivalents (laboratory of F. v. Loewenich and C. Bogdan).
Plasmodium berghei
P. berghei ANKA was maintained by periodic passages through
the vector Anopheles stephensi. For infection, sporozoites were
isolated from salivary glands of mosquitoes fed at least 18 days
earlier on mice containing circulating gametocytes (laboratories of
A. Hoerauf and M. Mota). Mice were infected by intravenous (i.v.)
injection of 20,000 P. berghei ANKA sporozoites. Parasite load in
the liver was measured 40 h p.i. by qRT PCR as described
previously [33].
Hepa1–6 cells growing on coverslips in 6-well plates were
stimulated with 200 units of IFN-c for 24 h before infection with
10,000 or 50,000 freshly isolated sporozoites per well (laboratory
of S. Specht).
Histology
To determine the extent of histological changes and the
numbers of T. gondii cysts in brains and livers of mice, tissue
samples were obtained at indicated time points after infection and
immediately fixed in 5% formalin and embedded in paraffin.
Sections (5 mm) were stained with hematoxylin and eosin and
examined by light microscopy. Numbers of inflammatory areas
were counted in 10 optical fields (200 magnification) in five
adjacent sections each per mouse by blinded duplicate evaluation
(S.H. and F.H.). Numbers of cysts were determined by
immunohistology using T. gondii-antiserum in 10 optical fields
(200 magnification) in five sections each per mouse. There were at
least four mice per group. All experiments were repeated at least
twice.
Immunofluorescence analysis of tissue culture cells infected with
P. berghei was performed on glass cover slips essentially according to
the protocol used earlier for T. gondii [26]. Irga6 was identified in
IFN-c-induced cells with rabbit anti-Irga6 antiserum 165 bleed 3
[34]. Sporozoites were identified microscopically by immunoflu-
orescence with the mouse monoclonal antibody 2E6 specific for
Hsp70 [35].
Cytokine concentrations
Cytokine concentrations were determined in sera and superna-
tants of homogenized brain and liver samples obtained from T.
gondii-infected mice. Homogenization was performed with two
rough glass slides in 1 ml PBS. Homogenized organ samples were
centrifuged at 12,000 rpm for 10 min at 4uC. The supernatants
were harvested and stored at 280uC. Serum was obtained from
blood samples by centrifugation at 12,000 rpm for 10 min at 4uC.
Serum was stored at 280uC. IFN- and TNF concentrations were
determined by ELISA (BD-Biosciences, San Diego, CA, USA).
Cytokine concentrations were normalized to the whole protein
concentration determined for each sample using the Roti-
Nanoquant kit (Roth, Karlsruhe, Germany).
Replication of T. gondii in primary bone marrow-derived
macrophages (B)
Primary bone marrow cells were obtained from bones of 8-
week-old mice. The femur and lower leg of mice were dissected
and muscles removed. The bones were transferred to cold sterile
PBS. The ends of the bone were removed with scissors and the
bone marrow was flushed with a syringe containing cold medium
(RPMI/FCS/Penicillin/Streptomycin). Bone marrow cells were
pooled and centrifuged at 1,200 rpm for 10 min at 4uC. The
supernatant was discarded and the cells were resuspended in
15 ml medium. Cells were plated at a concentration of 10
6 cells/
ml in 12-well-plates at 5610
5/well. Cells were differentiated to
macrophages by addition of 500 ml macrophage colony stimulat-
ing factor (MCSF) in medium and cultivated at 37uC and 5% CO2
as previously described [36]. After 5 days the supernatant was
exchanged with fresh MCSF in medium and cells were incubated
Irga6 Protects Mice against Toxoplasma gondii
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macrophages were released by pipetting following incubation in
PBS at 4uC and plated in 96-well plates at 10
5 cells/well and
stimulated with 0, 10, or 100 U/ml IFN-c (Calbiochem,
Schwalbach, Germany). After 24 h, cells were infected with
tachyzoites of RH strain of T. gondii expressing green fluorescent
protein (GFP) (a kind gift of D. Soldati-Favre, University of
Geneva) at a multiplicity of infection (MOI) of 5:1 (tachyzoites:
cells). After 2 h incubation, extracellular tachyzoites were removed
with the supernatant and cells were incubated with fresh medium
for another 48 h. Cells were harvested with cold media and
stained with a PE-tagged CD86-antibody (BD-Biosciences). The
percentage of infected cells was determined by flow cytometry on a
FACS Calibur (BD-Biosciences).
Replication of T. gondii in mouse bone marrow-derived
macrophages (K)
Primary bone marrow-derived macrophages were prepared
essentially as above except that supernatant from L2 mouse
fibroblasts was used as a source of MCSF. After induction of cells
for 24 h with IFN-c at several concentrations, cells were infected
with different multiplicities of T. gondii strain ME49 tachyzoites
freshly harvested from human foreskin fibroblast-cell cultures.
Incorporation of
3H-uracil into replicating tachyzoites was
measured essentially according to [27].
Statistics
Comparison of variables, including numbers of inflammatory
foci, numbers of microorganisms and cytokine concentrations,
between individual groups of mice were determined using
Student’s t-test, Welsh’s t-test or two-tailed Mann-Whitney test.
Levels of significance for mortality in mice were determined using
Fisher’s exact test. Probability (P) values of ,0.05 were considered
significant.
Results
Course of infection with L. mexicana, L. major, M.
tuberculosis, L. monocytogenes, and A. phagocytophilum
in Irga6
2/2 mice
Both Berlin (B) and Cologne (K) homozygous Irga6
2/2 mutant
mice were born at normal Mendelian ratios, were fertile, and did
not exhibit any gross anatomical or behavioral abnormalities and
the cellular composition and cellular phenotype of lymphoid
organs was unaffected by the mutation (unpublished results).
Groups of B-Irga6
2/2 mice on a C57BL/6-background and
Figure 1. Role of Irga6 in infection with L. mexicana and L. major. B-Irga6
2/2 and C57/BL6 control mice, in groups of 8 animals each, were
infected by injection into the left hind footpad of L. mexicana (A) or L. major (B). Infection-induced swelling was determined weekly and values
represent the mean differences in footpad thickness 6 SEM. K-Irga62/2 and C57BL/6 control mice were injected with 2610
5 (C) or 10
3 (D) L. major
into the ear dermis. Lesion development was assessed weekly and expressed as ellipsoid (mean+/2 SEM).
doi:10.1371/journal.pone.0020568.g001
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promastigotes into the hind footpad and infection-induced footpad
swelling was recorded as a measure of disease severity. L. mexicana-
infected animals developed slowly progressing lesions similar to,
but marginally larger than, those of control mice over the first 7
weeks p.i. (Figure 1A); even after several months, no substantial
differences were evident in lesion scores (not shown). L. major-
infected mice developed transient self-healing infections again
marginally larger in B-Irga6
2/2 than in control mice (Figure 1B).
Groups of K-Irga6
2/2 mice on the C57BL/6 background were
infected with L. major promastigotes in the dermis of the ear and
lesion volumes were measured weekly in three dimensions with a
caliper. One group of mice received a high promastigote dose
(2610
5), the other group a low dose (10
3) more closely resembling
the natural infection. For both infection doses there was no
significant difference between the K-Irga6
2/2 mice and the
heterozygous or homozygous wild-types (Figure 1C, D). The
lesions appeared at the same time, developed to the same maximal
size and healed in all infected animals. The tendency to larger
lesions noted in the Berlin group was not repeated in the Cologne
mice. Similarly, deficiency in Irga6 had no impact on the bacterial
burden in organs from B-Irga6
2/2 mice after i.v. infection with L.
monocytogenes EGD (Figure 2A) and K-Irga6
2/2 mice infected by
i.p. injection of L. monocytogenes showed no excess mortality
compared with wild-type C57BL/6 mice (Figure 2B). B-Irga6
2/2
mice showed no excess bacterial burden after aerosol infection
with M. tuberculosis (Figure 2C). K-Irga6
2/2 and wild-type
C57BL/6 mice were infected i.p. with the intracellular bacterial
pathogen, A. phagocytophilum, which replicates primarily in
neutrophils. Organs harvested at three timepoints after infection
were assayed by quantitative PCR for the bacterial ankA gene. The
course of the self-resolving infection was identical in wild-type and
K-Irga6
2/2 mice (Figure 2D). Taken together, these results
indicate that Irga6 is probably not significantly involved in
resistance against L. major and L. mexicana, L. monocytogenes, M.
tuberculosis and A. phagocytophilum.
Course of infection with T. gondii in Irga6
2/2 mice
We investigated the role of Irga6 in oral infection with the
intracellular protozoon T. gondii in B-Irga6
2/2 mice on the
susceptible C57BL/6 and the resistant 129Sv/J backgrounds.
Mice were orally infected with 10 cysts of T. gondii. The mortality
of B-Irga6
2/2 mice on the C57BL/6 background increased
significantly (p,0.05) compared to wild-type mice (Figure 3A). A
mortality of 60% in B-Irga6
2/2 mice was observed by day 24 p.i.
whereas wild-type mice showed a mortality of only 10% at the
Figure 2. Role of Irga6 in infection with M. tuberculosis, L. monocytogenes and A. phagocytophilum. A: Infection of B-Irga6
2/2 and wild type
C57BL/6 mice with L. monocytogenes. CFU were measured in spleen and liver as described in Materials and Methods. B: Infection of K-Irga6
2/2 and
wild-type C57BL/6 mice with L. monocytogenes. Survival curves were measured as described in Materials and Methods C: Infection of B-Irga6
2/2 mice
with M. tuberculosis. CFU were measured in spleen and lung as described in Materials and Methods D: Infection of K-Irga6
2/2 mice with A.
phagocytophilum. The bacterial load was measured by quantitative PCR in blood, spleen and lung at the indicated day post infection (p.i.) as
described in Materials and Methods. Means and SD from one experiment are shown.
doi:10.1371/journal.pone.0020568.g002
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2/2 mice on the
129Sv/J background were apparently somewhat more resistant to
infection compared to mice on the C57BL/6 background. All
wild-type 129Sv/J mice survived infection whereas the mortality
rate was 10% in 129Sv/J Irga6
2/2 mice during the observation
period (up to day 150; Figure 3B). Taken together, these results
indicated that Irga6 plays a role in resistance of C57BL/6 mice
against oral infection with T. gondii.
A preliminary experiment on the susceptibility of K-Irga6
2/2
mice on the C57BL/6 background to infection with the mouse-
avirulent strains, ME49 and DX, yielded an insignificant excess
mortality: of 22 wild-type and heterozygous animals, 1 died; of 9
Irga6
2/2 homozygous animals, 2 died. These mortality numbers
were originally interpreted conservatively to indicate that Irga6
deficiency did not lead to a significant susceptibility phenotype to
T. gondii [37]. However the finding of susceptibility in the B-
Irga6
2/2 C57BL/6 strain mice (Figure 3A) contradicted this
conclusion. To determine whether there was indeed a real
difference between the two mutant strains, B and K-Irga6
2/2
mice on C57BL/6 backgrounds were compared directly with wild-
type C57BL/6 in the Berlin laboratory. All mice were infected
with 10 cysts of the ME49 strain, either by the oral or
intraperitoneal routes. The B- and K-Irga6
2/2 strains behaved
essentially identically in this experiment (Figure 3C, D). Both
showed a weak but definite susceptibility phenotype relative to
wild-type following infection by the oral route, and a somewhat
greater susceptibility following infection by the intraperitoneal
route. In both groups, 50% of the Irga6
2/2 animals infected
intraperitoneally died in the acute phase of the infection followed
by prolonged survival. The experiment was terminated at 45 days.
To gain further insight into the increased susceptibility of
Irga6
2/2 mice to oral infection with T. gondii, we investigated
inflammatory changes and parasite loads in brains of infected wild-
type and B-Irga6
2/2 C57BL/6 and 129/SvJ mice (Figure 4 and
Figure S3). Four weeks after oral infection, the wild-type mice
showed meningeal inflammation but only few inflammatory
changes in the brain parenchyma compared with more pro-
nounced meningeal and parenchymal inflammation (mostly
mononuclear cells) in the Irga6
2/2 mice (Figure 4A). Numbers
of T. gondii cysts were significantly higher in the brains of
B-Irga6
2/2 mice compared to controls (Figure 4B). Taken
together, these results suggest that mice deficient in Irga6 suffer
from defective control of parasite replication resulting in increased
inflammatory responses.
Figure 3. Survival of Irga6
2/2 mice after oral and i.p. infection with T. gondii. Wild-type (open symbols) and B-Irga6
2/2 mice (closed
symbols) on the C57BL/6 (A) and 129Sv/J (B) background were infected orally with 10 cysts of the ME49 strain of T. gondii. There were at least 4 mice
in each group. Results shown are from one representative experiment of three experiments performed. Survival and time to death of K-Irga6
2/2
(C) and B-Irga6
2/2 (D) mice (closed symbols) and their respective wild-type controls (open symbols) were compared following oral and i.p. infection
with 10 cysts of the mouse-avirulent ME49 strain of T. gondii. All infections for this figure were performed in the Berlin laboratory.
doi:10.1371/journal.pone.0020568.g003
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surviving mice from the experiment shown in Figure 3C and 3D
above, in which B- and K-Irga6
2/2 strain mice were compared
directly for susceptibility to T. gondii infection. Mean inflammatory
scores (considering meningeal inflammation and parenchymal foci
of inflammation) [38] were more pronounced in Irga6
2/2 mice
compared to wild-type mice euthanized at day 45 p.i. regardless of
the route of infection and the origin of mice (data not shown).
IFN-c is the key cytokine for orchestration of immunity
against infection with T. gondii [8] and also controls the induction
of IRG proteins [39]. Hence, we determined concentrations
of IFN-c in brain homogenates and serum obtained from T.
gondii-infected wild-type C57BL/6 and B-Irga6
2/2 mice. Mean
concentrations of IFN-c were significantly elevated in brains but
not in serum in Irga6
2/2 compared to wild-type mice
(Figure 4C). In contrast, the concentration of TNF did not
differ significantly in brains in these animals (Figure 4D). These
results indicate that local IFN-c production is increased in
Irga6
2/2 mice, presumably due to the cellular reaction against
increased parasite loads and that the phenotype of the Irga6
2/2
mice is not due to a lack of IFN-c.
Irga6 contributes to the control of T. gondii replication in
IFN-c-stimulated macrophages
To determine whether Irga6 is involved in control of parasite
replication, bone marrow-derived macrophages (BMM) from
B-Irga6
2/2 mice were stimulated with IFN-c and infected with
RH tachyzoites. BMM from wild-type and Irga6
2/2 mice could
both be stimulated with IFN-c to block the replication of T. gondii
in a concentration-dependent manner. The replication block was
not complete but percentages of infected cells were significantly
higher in Irga6
2/2 than in wild-type BMM following stimulation
with 10 and 100 IFN-c U/ml (Figure 5A). Similar experiments
were performed with BMM from K-Irga6
2/2 mice, in which
replication of mouse-avirulent ME49 strain T. gondii in IFN-c-
stimulated cells was monitored by incorporation of
3H-uracil.
Again a highly significant loss of IFN-c-dependent control of
parasite proliferation was seen in the K-Irga6
2/2 cells compared
with the K-C57BL/6 wild-type cells (Figure 5B). Similar results
were reported earlier in K-Irga6
2/2 embryonic astrocytes [26]
and in mouse embryonic fibroblasts (unpublished). The greater
impairment in resistance seen in Figure 5B than in Figure 5A is
probably due to the lower MOI used in the experiment in
Figure 4. Inflammatory processes following T. gondii infection in the brains of B-Irga6
2/2 and wild-type mice. (A) Inflammatory foci
were detected histologically at 39 days after infection of B-Irga6
2/2 with ME49 strain T. gondii as described in Materials and Methods. (B) Cysts were
counted microscopically in brain homogenates obtained from infected mice 139 days after infection, as described in Materials and Methods. (C) IFN-c
and (D) TNF were determined by ELISA in brain homogenates and serum (C only) from B-Irga6
2/2 mice at 29 days after infection. Means 6 SD are
presented from 4 individual mice; results are representative for 3 experiments performed.
doi:10.1371/journal.pone.0020568.g004
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Irga6 contributes to IFN-c-mediated cell-autonomous control of
T. gondii, and are consistent with the significant but limited
susceptibility to low-dose infection with mouse-avirulent T. gondii in
vivo shown above (Figure 3).
P. berghei load in liver of wild-type and K-Irga6
2/2 mice
Irga6 is expressed constitutively in hepatocytes and is also
strongly induced in liver by IFN-c [39,40]. This distribution hinted
that Irga6 might act preferentially in the liver, and therefore be of
special relevance in resistance to the related parasite P. berghei,
which infects hepatocytes before infecting red blood cells and
causing malaria [41] We therefore assessed a possible effect of
Irga6 on P. berghei resistance by measuring parasite load during the
early replication phase in the liver using quantitative PCR for PbA
18S ribosomal RNA following infection of wild type C57BL/6 and
K-Irga6
2/2 mice with large doses of sporozoites from the ANKA
strain. No significant difference was detected over a total of 14
animals per genotype in three experiments (Figure 6A).
Failure of IRG proteins to accumulate on P. berghei
parasitophorous vacuole
If IRG proteins contribute to resistance against P. berghei in the
same way as they do against T. gondii, it seemed reasonable to look
for loading of Irga6 onto the PVM of P. berghei sporozoites
infecting IFN-c-induced liver cells. We looked with IRG-specific
antibody reagents for accumulation of Irga6 and other IRG
proteins at the P. berghei sporozoite parasitophorous vacuole in
IFN-c-induced Hep1-6 liver-derived cells infected with fresh,
mosquito-derived P. berghei (ANKA) sporozoites. No accumulation
of Irga6 (Figure 6B) or of any other IRG protein (not shown) was
detected at the P. berghei PV. The same result was found in several
other cell lines including primary C57BL/6 MEFs (not shown).
We tentatively conclude that the IFN-c-inducible IRG system does
not play a significant role in resistance to P. berghei in the C57BL/6
mouse.
Discussion
The present study shows that deficiency of Irga6/IIGP impairs
survival of mice whether orally or peritoneally infected with T.
gondii (Figure 3). The inflammatory response in brains of Irga6
2/2
mice was significantly increased compared to wild-type controls,
indicated by increased numbers of inflammatory foci and T. gondii
cysts as well as higher levels of IFN-c (Figure 4). By these criteria,
susceptibility to T. gondii was more pronounced in Irga6
2/2 mice
on a C57/BL6 than on a 129Sv/J background. These results,
accumulated from experiments based on two independent gene
knock-outs prepared in different laboratories (Cologne, Germany,
K, and Berlin, Germany, B) contradict an earlier suggestion [14],
based on preliminary data for one of the two knock-out strains,
that normal control of mouse-avirulent T. gondii infection in mice is
independent of Irga6. In addition, analysis of BMM from both
Irga6-deficient strains revealed an impaired IFN-c-mediated
control of T. gondii growth in vitro. These data can be added to
the results already reported, of a smaller but clear deficit in control
of T. gondii replication in IFN-c-treated astrocytes from Irga6-
deficient C57BL/6 mice [26]. Thus, Irga6/IIGP now clearly
belongs to the list of IRG proteins that contribute to defence
against T. gondii in vivo and in vitro.
In contrast, we found that deficiency of Irga6 did not influence
survival or pathogen load in mice upon infection with several other
intracellular pathogens including M. tuberculosis, L. monocytogenes and
A. phagocytophilum. Apparently slightly reduced resistance was found
to the two Leishmania species, L. major and L. mexicana, assayed on
the B-Irga6
2/2 mice (Figure 1A, B). If confirmed, this result
would be consistent with a report of increased mortality to
Leishmania in mice deficient in another IRG protein, Irgm3 [15].
However no equivalent trend towards susceptibility to L. major was
apparent in K-Irga6
2/2 mice (Figure 1C, D). Further experimen-
tation will be required to find out whether this difference is merely
a statistical accident. The association of IRG proteins with the
Leishmania parasitophorous vacuole is presently under investiga-
tion. It is unlikely that IRG proteins can contribute to resistance
against Leishmania without associating with the parasitophorous
vacuole. The situation with Chlamydia trachomatis L2 strain is
controversial. Irga6-deficient C57BL/6 mice of the Cologne strain
Figure 5. IFN-c-dependent control of replication of T. gondii in
bone-marrow-derived macrophages from wild-type and
Irga6
2/2 mice. (A) B-Irga6
2/2 and wild type mice: Bone-marrow
derived macrophages were pre-treated with IFN-c at indicated doses
and infected with GFP-expressing parasites of the mouse-virulent RH
strain of T. gondii at a parasite-cell ratio of 5:1. At 48 h post infection,
percentages of infected CD86-positive cells were determined by flow
cytometry. At zero infection the data record fluctuations around
background. Data shown are results 6 SD representative of 2
experiments performed. * p,0.05. A significant loss of IFN-dependent
control was seen in the Irga6-deficient cells (open columns).
(B): K-Irga6
2/2 and wild-type C57BL/6 mice: bone-marrow derived
macrophages were induced for 24 h with 10 units or 100 units IFN-c
and infected at MOI 0.1 with mouse-avirulent ME49-strain T. gondii.
Proliferation of T. gondii was measured by incorporation of
3H-uracil
between 48 and 72 h after infection. A highly significant loss of IFN-c-
dependent control was seen in the Irga6-deficient cells (white columns)
at both IFN-c concentrations.
doi:10.1371/journal.pone.0020568.g005
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pathogen both in vivo and in IFN-c-induced embryonic fibroblasts
in vitro [42]. However an earlier report exploited an RNAi
procedure in vitro to indicate that Irga6 may play a role in
resistance of IFN-c-induced mouse cells to this strain [43] and it
was also reported recently that IFN-c-induced Irga6-deficient
C57BL/6 embryonic fibroblasts from the Berlin strain lose
resistance to C. trachomatis L2 [44]. These discrepant results have
been obtained in different laboratories using different techniques
and will need to be reconciled.
For the first time, we have also explored the possible
contribution of IRG proteins to resistance to a malarial pathogen,
P. berghei, in mice. In view of the taxonomic affinity between
Toxoplasma and Plasmodium it was a reasonable expectation that
IRG proteins would behave in a similar manner towards both
apicomplexan parasites. However, the results do not support this
expectation. Since IRG proteins function cell-autonomously in the
cytoplasm, a reasonable assumption would be that any resistance
mediated by IRG proteins against Plasmodium would be initiated
during the intracellular replicative phase in hepatocytes. In the
case of Irga6, this seemed especially plausible in view of the
distinctive high constitutive expression of this IRG protein in the
liver driven by a dedicated hepatocyte-specific promoter [40], and
the extreme inducibility of liver Irga6 to IFN-c [19,40]. However,
quantitative PCR failed to find any tendency towards higher
parasite numbers in livers from Irga6-deficient than from wild-type
C57BL/6 mice (Figure 6A). Lastly, and perhaps most definitively,
no IRG proteins were found associated with the PV of P. berghei
infecting several different IFN-c-induced cell lines of liver and
non-liver origin. This was the case not only for Irga6 (Figure 6B),
but also for Irgb6, Irgd, Irgm1 and Irgm3 (data not shown).
Preparations were examined throughout the infection from the
first 30 minutes, with elongated sporozoites, to 12 hours after
infection immediately after the beginning of replication. At no
time was IRG protein loading observed. Since the resistance
mechanism of IRG proteins for T. gondii entails loading onto the
PVM [26] followed by disruption of the vacuolar membrane
[26,45] and death of the parasite [45] it seems clear that absence
of IRG loading onto P. berghei vacuoles implies lack of a resistance
function of IRG proteins for this parasite. For the moment,
therefore, we consider that IRG proteins in general, and Irga6 in
particular, are not involved in resistance of mice against P. berghei.
Since pathogen-derived mechanisms from both T. gondii
[27,46,47,48] and Chlamydia muridarum [42] can antagonise IRG
protein function and reduce or eliminate their loading onto
pathogen-containing vacuoles, a similar effect may also be at work
in P. berghei infection of mice. In the absence of any IRG protein
loading, such a virulence factor could operate freely in the cytosol
to inactivate IRG proteins before they access the vacuolar
membrane. Alternatively, the result could be due to expression
of a factor at the vacuolar membrane that repels IRG protein
loading. However, the principles of IRG protein loading onto
pathogen vacuoles have not yet been elucidated. Despite many
apparent similarities between the parasitophorous vacuoles of T.
gondii and P. berghei there may yet be structural differences relevant
to the IRG loading mechanism. Whether these constitute a
virulence mechanism in P. berghei against the IRG system will
depend on the ecological relationship between P. berghei and its
natural hosts.
Including Irga6, four mouse IRG genes have now been
disrupted and all have resulted in a more or less dramatic
susceptibility to infection with T. gondii. With mice on a mixed
C57BL/6 129Sv background 100% death within 14 days was seen
after i.p. infection with 20 cysts of the mouse-avirulent ME49
strain T. gondii in Irgm3
2/2 and Irgm1
2/2 mice [23,49].
Approximately 30% of Irgd
2/2 mice died during the acute stage
of infection and mortality increased to 70% by day 60 p.i. [49].
The intermediate acute susceptibility of Irga6
2/2 mice against
infection with T. gondii observed in susceptible C57BL/6 and
resistant 129Sv mice in the present study more closely resembles
Figure 6. The IRG system does not interact with P. berghei. (A) No effect of Irga6 deficiency on P. berghei replication in the liver. K-Irga6
2/2 and
wild-type C57BL/6 mice were infected intravenously with 20,000 fresh mosquito-derived P. berghei ANKA sporozoites. 40 hours after infection DNA
was prepared from livers for qPCR with primers specific for the P. berghei 18S gene as described in Materials and Methods. 14 mice from each strain
were assayed. (B) Irga6 does not accumulate on the P. berghei parasitophorous vacuole membrane. Hep1-6 cells were induced with 200 units of IFN-c.
After 24 h, cells were infected with fresh mosquito-derived sporozoites of P. berghei ANKA, fixed 6 h later and stained with a rabbit antiserum (165)
against Irga6 (green). 2 infected cells are illustrated (panels A-D and E–H). The sporozoites (white arrows) were identified with a mouse antibody (2E6)
directed against a P. berghei hsp70 (red). DAPI was used to identify nuclei of both the Hep1-6 and P. berghei.
doi:10.1371/journal.pone.0020568.g006
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observed in Irgd
2/2 mice [49], but without the later, progressive
mortality seen in the Irgd knock-out on a different genetic
background. The family of IRG proteins has been divided
structurally and functionally into a regulatory subgroup, the
GMS proteins, and an effector subgroup, the GKS proteins
[39,50]. For the moment, the data support the view that mice with
a loss of individual regulatory (GMS) GTPases (Irgm1 and Irgm3)
have stronger phenotypes than those with a loss of individual
effector (GKS) GTPases (Irgd and Irga6). Since the GMS proteins
probably regulate all the effector GTPases [50], the stronger
phenotypes with loss of Irgm1 and Irgm3 could perhaps be
anticipated.
The non-redundant requirement for at least four members of
the IRG family, now including Irga6, confirms the complex
integrated activity of the IRG system in organising cell-
autonomous resistance to T. gondii. The regulatory role of the
three GMS proteins on the GKS effector proteins is one part of
the story [50], while the cooperative binding interactions of
multiple effector proteins on the PV, leading ultimately to its
disruption [27] is another. Through results on Irgm1-deficient
mice the IRG system has been implicated in resistance to a
number of parasites in addition to chlamydia and T. gondii.
However it is likely that such results for pathogens other than C.
trachomatis and T. gondii can all be attributed to a general immune
deficiency caused indirectly by loss of Irgm1, and not to loss of a
direct resistance action by Irgm1 itself [25]. It is indeed
remarkable that the complex IRG system is so important for
mice in resistance to only a few pathogens. It is also remarkable
that the entire system has been lost in the primate lineage leading
to man [16]. However, in view of the irreplaceable status of the
mouse as the model of choice in experimental studies of
immunity, it is essential to understand the differences as well
as the similarities between the mouse and human immune
systems [51].
Supporting Information
Figure S1 Generation of Irga6/IIGP gene deletion in
Berlin. In the Max Planck Institute for Infection Biology, Berlin,
Irga6/IIGP was originally cloned by suppression subtractive
hybridization from splenocytes isolated from L. monocytogenes-
infected C57BL/6 mice [52]. The following strategy was
employed to generate a deletion of the Irga6/IIGP gene
(Figure S1). LAWRIST7-based cosmids MPMGc121F04152 and
MPMGc121E14552 from murine genomic 129/Ola cosmid library
(Deutsches Ressourcenzentrum fuer Genomforschung RZPD,
Berlin, Germany) were identified as Irga6/IIGP positive by PCR
and confirmed by sequencing. A 4684 bp EcoRI/PvuII fragment,
immediately upstream of the single coding exon of the Irga6 gene,
was cloned in front of a neomycin resistance cassette within a
pBluescript vector. A 590 bp PCR-amplified Irga6 fragment
immediately downstream of the Irga6 coding sequence was cloned
behind the selection cassette followed by a herpes simplex virus
thymidine kinase cassette (Figure S1A). The linearised targeting
vector was electroporated into E14.1 ES cells [53]. Homologous
recombinants were detected by PCR and confirmed by Southern
blot hybridization with 59 or 39 flanking probes. Single integration
was verified by probing the Southern blots with the neomycin
resistance cassette. Correctly targeted ES cell clones were injected
into C57BL/6 blastocysts and transferred to foster mothers.
Chimeric progeny were backcrossed either to C57BL/6 or
129Sv/J mice, and germ line transmission of the targeted allele
was confirmed by Southern blot. The mice used in these
experiments were backcrossed to the C57BL/6 background for at
least 7 generations or to the 129/SvJ background for at least 4
generations. Genotyping for the Irga6 mutation was performed by
PCR with the following primers: 59- CTGCTGACCTAGTGAA-
TATCATC -39 (Irga6 forward), 59- CGCCTTCTTGACGAGT-
TCTTCTG (Neomycin forward), and 59- AATGTGGATACAT-
AATCAGTAAAGG -39(Irga6 reverse). The endogenous, non-
mutated locus gave rise to a 527 bp fragment, while the targeted
locus produced an 810 bp fragment (Figure S1B). Generation of
bone marrow-derived macrophages, stimulation with IFN-c,a n d
analysis of Irga6 deficiency by Western Blot with mAb 10E7 (Figure
S1C). were performed as described previously PCR primers for
generation of the short-arm probe (italic: Irga6-specific portion)
were: 59-ACGCGAGGGTGAGTCCCAATGATCAGG and 59-ACGC-
GAGAGAGGCTGCATTGGCTGTGGT. PCR primers for gen-
eration of the long-arm probe were: CTTGGCTAAGGGTA-
AGGCCT and AGAGGCCCTCTGCCTTAGC.
(TIF)
Figure S2 Generation of Irga6/IIGP gene deletion in
Cologne. At the Institute for Genetics in Cologne, Irga6/IIGP
was originally cloned from IFNc-induced C57BL/6 mouse
embryonic fibroblasts by suppression subtractive hybridization
[39]. The following strategy was employed to generate a deletion
of the Irga6/IIGP gene. A 4kb BamH1 fragment, containing the
whole of the coding exon 2 of Irga6 with about 2 kb of 59 intronic
sequence and about 1 kb of 39-untranslated sequence, was
subcloned from the C57BL/6 strain derived genomic BAC clone
RP23-19A12 into the blunted Sal1 site of the targeting vector,
pEasyFlox [54] 59 and 39 homology arms were generated by PCR
amplification from BAC sublones. Additional restriction sites
were added with the primers to enable the 59 and 39 homology
arms to be cloned into the Xho1 and Not1 sites of pEasyFlox
respectively. The completed targeting construct (Figure S2A) was
linearised and transfected into Bruce4 ES cells derived from
C57BL/6 Thy1.1 mice [55]. Of 350 G418 and gancyclovir-
resistant colonies, 3 were identified as homologous integrants, of
which one was probably partial. The remaining two clones, 1B10
and 3A3 were injected into CB20 blastocysts and high-level
chimeras generated. Two chimeras derived from clone 1B10
transmitted the mutant allele to 100% of progeny. A completely
Irga6-deficient mouse was generated by crossing germ-line-
transmitting offspring to the C57BL/6 Cre-deleter mouse [56]
Positive heterozygous progeny were intercrossed to generate
homozygous Irga6-deficient progeny. All expected genotypes
were generated in mendelian ratios, assayed by Southern blotting
of tail-tip DNA. Embryonic fibroblasts prepared from the
homozygous line of Irga6-deficient mice showed no signal in
Western blot with rabbit anti-Irga6 serum 24 hr after induction
with 100 U/ml IFN-c (Figure S2B).
(TIF)
Figure S3 Histological changes in brains of wildtype
and B-Irga6-deficient mice following infection with T.
gondii. Histological changes in brains of mice infected orally with
10 cysts of the ME49 strain of T. gondii. At 29 (C57BL/6-
background, A, B) and 139 (129Sv/J- background, E, F) days post
infection brains of mice were obtained, sections prepared, and
stained with H&E. Arrows in A, B, E, and F indicate meninges;
arrowheads indicate areas of focal inflammation. To visualize
parasites, sections of brains obtained at day 29 post infection were
stained with an anti-T. gondii serum (C,D); T. gondii cysts are
indicated by arrows and parasitophorous vacuoles are indicated by
arrowheads.
(TIF)
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